MM4TB (More Medicines for Tuberculosis)

Download Profile PDF
At a Glance
  • Status: Completed Consortium
  • Year Launched: 2011
  • Initiating Organization: European Commission
  • Initiator Type: Government
  • Disease focus:
    Tuberculosis
  • Location: International

Abstract

The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), which delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment.

Mission

The MM4TB research consortium has been assembled to discover anti-infective agents that will combat TB. Evolved from the FP6 project, New Medicines for TB (NM4TB) - which successfully delivered a candidate drug for clinical development two years ahead of schedule - the MM4TB team will apply an integrated approach that includes tripartite screening strategies and medicinal chemistry, functional genomics and structural biology. This combination of approaches is a broad strategy to discover new compounds, perform pharmacological validation, identify targets, and analyze a variety of mechanisms of action during Mycobacterium tuberculosis (M. tb) infection.

Consortium History

The consortium’s original project was titled New Medicines for TB (NM4TB), which successfully discovered the benzothiazinone (BTZ) series, now in late stage preclinical development.  Now, MM4TB seeks to discover more anti-infective agents that will combat TB.

Structure & Governance

The consortium is overseen by the European Commission’s 7th Framework Programme

Financing

Funding for MM4TB is made available by the European Commission’s 7th Framework Programme

Impact/Accomplishment

A resource list of MM4TB publications can be found on their website under the “Publications” tab.  

Points of Contact

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
BATIMENT CE 3316 STATION 1
1015 LAUSANNE
Switzerland
Activity type: Higher or Secondary Education Establishments
Administrative contact: Stewart Cole
Tel.: +41216931851
Fax: +41216931790

Sponsors & Partners

The École Polytechnique Fédérale de Lausanne (EPFL)

AstraZeneca

Sanofi-aventis

Alere

Vichem

Cellworks

CDD

Tydock

Uppsala University

Pavia University

University of Cambridge

Queen Mary’s University

University of London

Padova University

Comenius University

Piemonte Oreintale University

Basque Country University

University of Zaragoza

ETH Zurich University

Cape Town Unversity

Institute Pasteur de Paris

Institute Pasteur de Lille

Bach Institute of Biochemistry

John Innes Center

Indian Academy of Sciences

Last Updated: 06/20/2017
The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.
Register your consortium  
All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.